Core Viewpoint - Lexaria Bioscience Corp. announced positive pharmacokinetic results from its Human Study 3, demonstrating that its oral DehydraTECH-tirzepatide can achieve comparable blood concentration levels to the injected Zepbound® [1][2][10] Study Design and Results - The study involved 10 participants receiving a weekly injection of Zepbound® and 9 participants taking DehydraTECH-tirzepatide capsules daily over the same period [3] - Peak blood levels for injected Zepbound® were generally higher but showed a decline after Day 2, while DehydraTECH-tirzepatide levels increased steadily and were still rising on Day 8 [4][5] - 80% of injected participants experienced peak levels on Day 2, whereas 50% of DehydraTECH-tirzepatide participants peaked on the final day, indicating ongoing absorption [4] Side Effects and Efficacy - DehydraTECH-tirzepatide showed a 47% reduction in adverse events compared to injected Zepbound®, with only 20 adverse events reported for the oral version versus 38 for the injection [5][6] - Gastrointestinal side effects were reduced by 54% with DehydraTECH-tirzepatide, while glycemic performance indicators remained comparable between the two formulations [6] Future Studies - The company is conducting a 12-week study in Australia to further evaluate the effectiveness of DehydraTECH-tirzepatide, with dosing starting at 20 mg/day and escalating to 40 mg/day [7][8] - The ongoing study aims to assess steady-state blood levels over an extended duration, which could position Lexaria as a significant player in the GLP-1 weight loss and diabetes control markets [7][8] Competitive Landscape - Currently, there is no oral version of tirzepatide available, as it is only sold as an injection [9][12] - Lexaria's DehydraTECH technology has previously shown promise in delivering other GLP-1 drugs, indicating potential for a competitive oral alternative in the market [11][12]
Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound